Patients with CD37-positive (CD37^pos) HL and B- and T-cell non-Hodgkin lymphoma were treated with autologous anti-CD37 CAR T cells coexpressing a tEGFR. Median vein-to-vein time from apheresis to infusion of CAR T cells was 10 days. The CAR T cells expanded after infusion and showed clinical efficacy in heavily pretreated patients. A prolonged CRS and prolonged cytopenia were also observed. B-NHL, B-cell non-Hodgkin lymphoma; CAR, chimeric antigen receptor; CRS, cytokine release syndrome; HL, Hodgkin lymphoma; tEGFR, truncated epithelial growth factor receptor; T-NHL, T-cell non-Hodgkin lymphoma.